Fourth-Quarter and Full-Year 2019 Orphan and Rheumatology Segment Results
}
KRYSTEXXA: MIRROR Open-Label Trial Data Support Our Immunomodulation Strategy
79 Percent Complete Response Rate Achieved in MIRROR Open-Label Trial
79%
MIRROR OL
complete response rate
VS.
42%
Phase 3
complete response rate
Well tolerated
Response Rate Based on sUA <6mg at
Month 6
Response Rate of KRYSTEXXA plus Methotrexate
Dramatically Higher than KRYSTEXXA Alone
KRYSTEXXA Alone
KRYSTEXXA plus Methotrexate
100%
79%
80%
100%
90%
80%
70%
60%
50%
40%
30%
20%
42%
10%
0%
Phase 3 Clinical Trials
n=85
MIRROR OL
Albert
Peterson Botson
n=14
n=10
n=10
Phase 3 Clinical Trials (blinded, placebo-controlled): 36 out of 85 patients achieved a complete response. MIRROR OL (open-label): 11 out of 14 patients enrolled achieved a complete response.
Albert Case Series (open-label): 8 out of 10 patients achieved a complete response. Arthritis & Rheumatology, 2019;71(S10): Abstract 1236.
Peterson Botson Case Series (open-label): 10 out of 10 patients achieved a complete response. Annals of the Rheumatic Diseases, 2019;78(2):SAT0404.
Note: Data from separate clinical trials may not be directly comparable due to differences in trial protocols, conditions and patient populations.
HORIZON
26View entire presentation